Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

  • Awaiting development
  • GID-TA11721
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Fenebrutinib within its marketing authorisation for treating multiple sclerosis ID6543